ICER reaffirms Qsymia as most cost-effective obesity treatment in final report

Paul Schloesser

Associate Editor

Last July, the cost-effectiveness drug watchdog ICER released a preliminary draft report that Vivus’ Qsymia was the most cost-effective option for weight loss. That decision …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ICER reaffirms Qsymia as most cost-effective obesity treatment in final report

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

ICER reaf­firms Qsymia as most cost-ef­fec­tive obe­si­ty treat­ment in fi­nal re­port

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ICER reaffirms Qsymia as most cost-effective obesity treatment in final report